A new research project at the University of Arizona Center for Innovation in Brain Science will apply a big-data approach, using bioinformatics and computational modeling, to better understand the systems biology of Alzheimer's and other neurodegenerative diseases.
This research will seek to identify patient-specific therapeutic targets and evaluate the effectiveness and safety of drug combinations to treat Alzheimer's disease.
Principal investigator Rui Chang, PhD, center member and an associate professor in the Department of Neurology in the College of Medicine - Tucson, has been awarded a $1.6 million grant from the National Institute on Aging (NIA) of the National Institutes of Health that will allow his team to leverage big data to attempt to close the gap on cognitive decline and healthy aging.
The two-year project will screen for small molecules and repurpose FDA-approved investigational and experimental drugs, or drug combinations, for Alzheimer's disease, employing big data to capture the complexity of neurodegenerative diseases, which are driven by an array of factors, including genetics, aging, gender, environment and disease stage.
We're able to go from patients to the single-cell level and use predictive models to integrate data that - thanks to this grant - now allows us to identify and validate key therapeutics in a cell-type specific way across the spectrum of age-associated neurodegenerative diseases." Dr. Rui Chang, principal investigator Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology